Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Account Payables (2016 - 2025)

OptimizeRx (OPRX) has disclosed Change in Account Payables for 16 consecutive years, with -$401000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 33.06% to -$401000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$520000.0 through Dec 2025, down 622.22% year-over-year, with the annual reading at -$520000.0 for FY2025, 622.22% down from the prior year.
  • Change in Account Payables hit -$401000.0 in Q4 2025 for OptimizeRx, down from $55000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.3 million in Q2 2024 to a low of -$1.4 million in Q2 2025.
  • Historically, Change in Account Payables has averaged -$49013.6 across 5 years, with a median of -$122985.5 in 2021.
  • Biggest five-year swings in Change in Account Payables: skyrocketed 1074.64% in 2022 and later crashed 4193.47% in 2023.
  • Year by year, Change in Account Payables stood at -$164837.0 in 2021, then surged by 433.27% to $549354.0 in 2022, then crashed by 183.92% to -$461000.0 in 2023, then dropped by 29.93% to -$599000.0 in 2024, then surged by 33.06% to -$401000.0 in 2025.
  • Business Quant data shows Change in Account Payables for OPRX at -$401000.0 in Q4 2025, $55000.0 in Q3 2025, and -$1.4 million in Q2 2025.